Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced that the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin achieved an overall survival ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE